Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

Ligand Pharmaceuticals Incorporated is revising upward its previous revenue and net income guidance for the fourth quarter and full year 2013 as a result of higher-than-expected sales of Captisol® material.

4 Dec 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Wild blueberries: 2 cups a day may keep the doctor away

Wild blueberries are a rich source of phytochemicals called polyphenols, which have been reported by a growing number of studies to exert a wide array of protective health benefits. A new study by researchers at the University of Maine adds to this growing body of evidence.

6 Nov 2013

Obese people experience substantial weight loss three years after bariatric surgery

In 3-year follow-up after bariatric surgery, substantial weight loss was observed among individuals who were severely obese, with most of the change occurring during the first year; however, there was variability in the amount of weight loss, as well as in diabetes, blood pressure, and lipid outcomes, according to a study published online by JAMA.

5 Nov 2013

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

Research from Boston University School of Medicine suggests that testosterone treatment in hypogonadal (testosterone deficient) men restores normal lipid profiles and may reduce the risk of cardiovascular disease. These finding currently appear online in the International Journal of Clinical Practice.

24 Oct 2013

FDA issues final approval for Lupin's sNDA for Antara capsules

Pharma Major Lupin Limited announced today that it has received final approval for its supplemental New Drug Application for Antara (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration.

23 Oct 2013

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin-based protein therapeutics, both companies announced today.

16 Oct 2013

Study shows PTSD increases individual's risk of metabolic syndrome

People suffering from post-traumatic stress disorder (PTSD) face a greater risk of cardiovascular disease and death. A new study involving a comprehensive review of the medical literature shows that PTSD also increases an individual's risk of metabolic syndrome.

3 Oct 2013

Spanish scientists discover melatonin consumption helps control weight gain

Melatonin is a natural hormone segregated by the body and melatonin levels generally increase in the dark at night. It is also found in fruit and vegetables like mustard, Goji berries, almonds, sunflower seeds, cardamom, fennel, coriander and cherries.

26 Sep 2013

Being overweight but metabolically healthy is not linked with increased risk of heart attack

Metabolically healthy women have the same cardiovascular disease risk regardless of their BMI, according to research presented at the ESC Congress today by Dr S-ren Sk-tt Andersen and Dr Michelle Schmiegelow from Denmark.

2 Sep 2013

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease in patients with mild dyslipidemia.

30 Aug 2013

Many women die due to Cad, yet less likely to receive preventive recommendations

Despite coronary artery disease (CAD) killing at least as many women as men each year, women are still today less likely to receive preventive recommendations, such as lipid-lowering therapy, aspirin, and lifestyle advice, than are men at a similar risk level.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Study: Heart disease emerges as number one killer among Indians

Heart disease has emerged as the number one killer among Indians, according to a recent study by the Registrar General of India ( RGI) and the Indian Council of Medical Research (ICMR).

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Dyslipidemia News and Research

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Wild blueberries: 2 cups a day may keep the doctor away

Obese people experience substantial weight loss three years after bariatric surgery

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

FDA issues final approval for Lupin's sNDA for Antara capsules

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Study shows PTSD increases individual's risk of metabolic syndrome

Spanish scientists discover melatonin consumption helps control weight gain

Being overweight but metabolically healthy is not linked with increased risk of heart attack

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Many women die due to Cad, yet less likely to receive preventive recommendations

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Study: Heart disease emerges as number one killer among Indians

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News